GlassScriptPhysician profile
Ami N Shah
NPI 1942596366
$151,148.90
in general payments reported to CMS, 2019-2025
10 companies · $60K in 2025
The $60K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,635 · 2020: $6,099 · 2021: $3,064 · 2022: $5,437 · 2023: $42K · 2024: $30K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Consulting Fee: $32K · Food and Beverage: $2,133 · Travel and Lodging: $1,979 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $615 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $95,017.50 |
| Consulting Fee | $32,045.00 |
| Food and Beverage | $2,132.92 |
| Travel and Lodging | $1,978.91 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $614.75 |
| Education | $124.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $78,758.47 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $40,026.03 | 2022-2025 | Datroway, Enhertu |
| Lilly USA, LLC | $7,529.80 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $7,024.02 | 2024-2025 | |
| Taiho Oncology, INC. | $6,098.50 | 2020 | |
| Daiichi Sankyo INC. | $3,986.87 | 2024-2025 | Enhertu |
| Astrazeneca Uk Limited | $3,052.50 | 2021 | |
| Abbvie INC. | $2,734.80 | 2019 | |
| Pfizer INC. | $1,912.21 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.